Chordomas are primary malignant bone tumors that arise in the axial skeleton, believed to originate from remnants of embryologic notochordal cell rests. Multicentric origin of chordoma is extremely rare. To our literature search, we found only three cases of multicentric chordoma in adults. We report a first case of multicentric chordoma in pediatric age group. A 14-month-old child presented with torticolis and left upper limb monoparesis, imaging showed expansile bony destructive lesion in clivus and dorsal spine simultaneously. The child underwent laminectomy, decompression of cord, excision of lesion, and histopathology was suggestive of chordoma. Pediatric chordomas are aggressive tumors, require multidisciplinary management with maximal safe resection followed by radiotherapy (conventional and/or proton). Even with multidisciplinary management, pediatric chordomas have high morbidity and mortality.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5588641 | PMC |
| http://dx.doi.org/10.4103/jpn.JPN_157_16 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study.
ESMO Open
June 2023
Aix Marseille University (AMU), APHM Hopital La Timone, Medical Oncology Unit, APHM, Marseille, France. Electronic address:
Background: REGOBONE multicohort study explored the efficacy and safety of regorafenib for patients with advanced bone sarcomas; this report details the cohort of patients with relapsed advanced or metastatic chordoma.
Methods: Patients with relapsed chordoma progressing despite 0-2 prior lines of systemic therapy, were randomised (2 : 1) to receive regorafenib (160 mg/day, 21/28 days) or placebo. Patients on placebo could cross over to receive regorafenib after centrally-confirmed progression.
Reconstruction and Cerebrospinal Fluid Leaks in Endoscopic Endonasal Approach for the Management of Clival Chordomas-A Systematic Review.
Indian J Otolaryngol Head Neck Surg
December 2022
Department of Otorhinolaryngology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Trust, Birmingham, B15 2TH UK.
The success of the endoscopic endonasal approach (EEA) to surgically manage clival chordomas (CC) relies on robust repair methods to reduce complications, such as cerebrospinal fluid (CSF) leaks. Our study aims to evaluate the existing literature to assess reconstructive techniques utilised and post-operative CSF leak rates in this cohort. A systematic review and analysis was performed of all published data related to CC patients managed with an EEA.
View Article and Find Full Text PDFIndolent multicentric chordoma - A previously undescribed entity: A Case report and literature review.
Surg Neurol Int
August 2022
Kenneth R. Peak Presidential Distinguished Chair Vice Chairman and Residency Program Director Department of Neurosurgery Director, Kenneth R. Peak Brain and Pituitary Tumor Treatment Center Professor of Neurosurgery, The Houston Methodist Research Institute, Weill Cornell Medical College and Texas A&M Medical School, Houston, Texas, United States.
Background: Chordomas are rare neuraxial tumors arising from remnants of primitive notochord. They are generally slow-growing malignant neoplasms. Only four adult cases of multicentric chordomas have been reported, all with aggressive and rapid growth.
View Article and Find Full Text PDFMulticentric Chordoma With Initial Resection by Bilateral Transcondylar Approach: 2-Dimensional Operative Video.
Oper Neurosurg (Hagerstown)
January 2022
Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Chordoma is a rare skull base tumor with malignant behavior.1-3 It invades locally with high recurrences, metastasizes distally, and seeds after interventions.1-4 Chordoma exemplifies the malignant progression doctrine as it accumulated genetic mutations.
View Article and Find Full Text PDFDrug combination screening as a translational approach toward an improved drug therapy for chordoma.
Cell Oncol (Dordr)
December 2021
Center for Medical Research, Medical University of Graz, Graz, Austria.
Article Synopsis
- Drug screening identified EGFR inhibitors as potential treatments for chordoma, with afatinib currently in a Phase II trial.
- A screening of 133 cancer drugs evaluated combinations with afatinib and erlotinib, identifying synergistic effects in certain combinations, notably with crizotinib and panobinostat.
- Promising drug combinations could enhance the effectiveness of EGFR therapies in chordoma, suggesting future treatment options that incorporate established chemotherapy drugs.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!